Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S Levy

Showing results (1201-1210 of 1,312) with videos related to

Pageof 132
Sort By:
Atherosclerosis|January 26, 2015
Pharmacogenomic interaction between the Haptoglobin genotype and vitamin E on atherosclerotic plaque progression and stabilityHilla-Lee Veiner, Rostic Gorbatov, Moshe Vardi, et al.
British Journal of Haematology|May 16, 2013
Health-related quality of life and symptoms in patients with myelofibrosis treated with ruxolitinib versus best available therapyClaire N Harrison, Ruben A Mesa, Jean-Jacques Kiladjian, et al.
Food and Chemical Toxicology : an International Journal Published for the British Industrial Biological Research Association|March 15, 2002
Hazard identification by methods of animal-based toxicologyS M Barlow, J B Greig, J W Bridges, et al.
International Journal of Molecular Sciences|September 13, 2025
Rescue of <i>Iqsec2</i> Knockout Mice with Human IQSEC2 Adeno-Associated Virus Mediated Gene TherapyDivyalakshmi Soundararajan, Emi Kouyama-Suzuki, Yoshinori Shirai, et al.
Antioxidants & Redox Signaling|August 8, 2009
Haptoglobin: basic and clinical aspectsAndrew P Levy, Rabea Asleh, Shany Blum, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 21, 2013
Effect of ruxolitinib therapy on myelofibrosis-related symptoms and other patient-reported outcomes in COMFORT-I: a randomized, double-blind, placebo-controlled trialRuben A Mesa, Jason Gotlib, Vikas Gupta, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 10, 2015
Randomized, Double-Blind, Phase II Study of Ruxolitinib or Placebo in Combination With Capecitabine in Patients With Metastatic Pancreatic Cancer for Whom Therapy With Gemcitabine Has FailedHerbert I Hurwitz, Nikhil Uppal, Stephanie A Wagner, et al.
The Journal of Allergy and Clinical Immunology. in Practice|July 6, 2026
Vaccination for Patients With Immunosuppression and Altered Immunity: A Workgroup Report from the AAAAI Adverse Reactions to Drugs, Biologics, and Vaccines Committee and the Autoimmunity and Altered Immune Response CommitteeMildred Kwan, Blanka M Kaplan, Krista Shaw, et al.
Hypertension (Dallas, Tex. : 1979)|January 15, 2019
B-Cell Deficiency Lowers Blood Pressure in MiceLuke S Dingwell, Eric A Shikatani, Rickvinder Besla, et al.
Orphanet Journal of Rare Diseases|February 16, 2021
Long-term health-related quality of life in patients treated with subcutaneous C1-inhibitor replacement therapy for the prevention of hereditary angioedema attacks: findings from the COMPACT open-label extension studyWilliam R Lumry, Bruce Zuraw, Marco Cicardi, et al.
Pageof 132

Showing results (1201-1210 of 1,312) with videos related to

Sort By:
Pageof 132
Atherosclerosis|January 26, 2015
Pharmacogenomic interaction between the Haptoglobin genotype and vitamin E on atherosclerotic plaque progression and stabilityHilla-Lee Veiner, Rostic Gorbatov, Moshe Vardi, et al.
British Journal of Haematology|May 16, 2013
Health-related quality of life and symptoms in patients with myelofibrosis treated with ruxolitinib versus best available therapyClaire N Harrison, Ruben A Mesa, Jean-Jacques Kiladjian, et al.
Food and Chemical Toxicology : an International Journal Published for the British Industrial Biological Research Association|March 15, 2002
Hazard identification by methods of animal-based toxicologyS M Barlow, J B Greig, J W Bridges, et al.
International Journal of Molecular Sciences|September 13, 2025
Rescue of <i>Iqsec2</i> Knockout Mice with Human IQSEC2 Adeno-Associated Virus Mediated Gene TherapyDivyalakshmi Soundararajan, Emi Kouyama-Suzuki, Yoshinori Shirai, et al.
Antioxidants & Redox Signaling|August 8, 2009
Haptoglobin: basic and clinical aspectsAndrew P Levy, Rabea Asleh, Shany Blum, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 21, 2013
Effect of ruxolitinib therapy on myelofibrosis-related symptoms and other patient-reported outcomes in COMFORT-I: a randomized, double-blind, placebo-controlled trialRuben A Mesa, Jason Gotlib, Vikas Gupta, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 10, 2015
Randomized, Double-Blind, Phase II Study of Ruxolitinib or Placebo in Combination With Capecitabine in Patients With Metastatic Pancreatic Cancer for Whom Therapy With Gemcitabine Has FailedHerbert I Hurwitz, Nikhil Uppal, Stephanie A Wagner, et al.
The Journal of Allergy and Clinical Immunology. in Practice|July 6, 2026
Vaccination for Patients With Immunosuppression and Altered Immunity: A Workgroup Report from the AAAAI Adverse Reactions to Drugs, Biologics, and Vaccines Committee and the Autoimmunity and Altered Immune Response CommitteeMildred Kwan, Blanka M Kaplan, Krista Shaw, et al.
Hypertension (Dallas, Tex. : 1979)|January 15, 2019
B-Cell Deficiency Lowers Blood Pressure in MiceLuke S Dingwell, Eric A Shikatani, Rickvinder Besla, et al.
Orphanet Journal of Rare Diseases|February 16, 2021
Long-term health-related quality of life in patients treated with subcutaneous C1-inhibitor replacement therapy for the prevention of hereditary angioedema attacks: findings from the COMPACT open-label extension studyWilliam R Lumry, Bruce Zuraw, Marco Cicardi, et al.
Pageof 132